Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 550

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Open access
Fenaux, Pierre, Platzbecker, Uwe, Mufti, Ghulam J., Garcia-Manero, Guillermo, Buckstein, Rena, Santini, Valeria, Díez-Campelo, María, Finelli, Carlo, Cazzola, Mario, Ilhan, Osman, Sekeres, Mikkael A., Falantes, José F., Arrizabalaga, Beatriz, Salvi, Flavia, Giai, Valentina, Vyas, Paresh, Bowen, David, Selleslag, Dominik, DeZern, Amy E., Jurcic, Joseph G., Germing, Ulrich, Götze, Katharina S., Quesnel, Bruno, Beyne-Rauzy, Odile, Cluzeau, Thomas, Voso, Maria-Teresa, Mazure, Dominiek, Vellenga, Edo, Greenberg, Peter L., Hellström-Lindberg, Eva, Zeidan, Amer M., Adès, Lionel, Verma, Amit, Savona, Michael R., Laadem, Abderrahmane, Benzohra, Aziz, Zhang, Jennie, Rampersad, Anita, Dunshee, Diana R., Linde, Peter G., Sherman, Matthew L., Komrokji, Rami S., List, Alan F.·2020·New England Journal of Medicine

Abstract

BACKGROUND: Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed promising results in a phase 2 study. METHODS: In a double-blind, placebo-controlled, phase 3 trial, we randomly assigned patients with very-low-risk, low-risk, or intermediate-risk myelodysplastic syndromes (defined according to the Revised International Prognostic Scoring System) with ring sideroblasts who had been receiving regular red-cell transfusions to receive either luspatercept (at a dose of 1.0 up to 1.75 mg per kilogram of body weight) or placebo, administered subcutaneously every 3 weeks. The primary end point was transfusion independence for 8 weeks or longer during weeks 1 through 24, and the key secondary end point was transfusion independence for 12 weeks or longer, assessed during both weeks 1 through 24 and weeks 1 through 48. RESULTS: Of the 229 patients enrolled, 153 were randomly assigned to receive luspatercept and 76 to receive placebo; the baseline characteristics of the patients were balanced. Transfusion independence for 8 weeks or longer was observed in 38% of the patients in the luspatercept group, as compared with 13% of those in the placebo group (P<0.001). A higher percentage of patients in the luspatercept group than in the placebo group met the key secondary end point (28% vs. 8% for weeks 1 through 24, and 33% vs. 12% for weeks 1 through 48; P<0.001 for both comparisons). The most common luspatercept-associated adverse events (of any grade) included fatigue, diarrhea, asthenia, nausea, and dizziness. The incidence of adverse events decreased over time. CONCLUSIONS: Luspatercept reduced the severity of anemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who had been receiving regular red-cell transfusions and who had disease that was refractory to or unlikely to respond to erythropoiesis-stimulating agents or who had discontinued such agents owing to an adverse event. (Funded by Celgene and Acceleron Pharma; MEDALIST ClinicalTrials.gov number, NCT02631070; EudraCT number, 2015-003454-41.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1908892

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 550

Metadata

Authors
Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia-Manero, G., Buckstein, R., Santini, V., Díez-Campelo, M., Finelli, C., Cazzola, M., Ilhan, O., Sekeres, M. A., Falantes, J. F., Arrizabalaga, B., Salvi, F., Giai, V., Vyas, P., Bowen, D., Selleslag, D., DeZern, A. E., Jurcic, J. G., Germing, U., Götze, K. S., Quesnel, B., Beyne-Rauzy, O., Cluzeau, T., Voso, M.-T., Mazure, D., Vellenga, E., Greenberg, P. L., Hellström-Lindberg, E., Zeidan, A. M., Adès, L., Verma, A., Savona, M. R., Laadem, A., Benzohra, A., Zhang, J., Rampersad, A., Dunshee, D. R., Linde, P. G., Sherman, M. L., Komrokji, R. S., & List, A. F.
Venue
New England Journal of Medicine
Published
2020-01-09
Volume
382
Issue
2
Pages
140-151
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2998901800
Cited by
550
References
43
FWCI
46.45
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.